Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01018186 · ClinicalTrials.gov registry record · Phase 3

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

A Phase 3 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
503
Enrollment target

NCT01018186 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 503 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01018186, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
503 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444

Interventions

  • DRUG Fluticasone propionate
  • DRUG Fluticasone Furoate/GW642444

Trial Details

FieldValue
Enrollment Target 503 participants
Start Date 2009-10-19
Est. Completion 2011-05-12
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT01018186

The ClinicalTrials.gov registry entry for NCT01018186 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Fluticasone propionate is the first listed.

NCT01018186 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01018186 about?

NCT01018186 is a clinical study titled "Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study". The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444

What is the current status of trial NCT01018186?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 503 participants. The study started on 2009-10-19. Estimated completion is 2011-05-12.

What interventions are being tested in trial NCT01018186?

The interventions under investigation include: Fluticasone propionate (DRUG), Fluticasone Furoate/GW642444 (DRUG).

Who is sponsoring clinical trial NCT01018186?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.